Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

504914 CNQX - CAS 115066-14-3 - Calbiochem

504914
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
115066-14-3C₉H₄N₄O₄

Products

Catalogue NumberPackaging Qty/Pack
5.04914.0001 Sklená flaša 10 mg
Description
OverviewA potent and competitive antagonist for AMPA/kainate receptors (Ki = 0.6 - 2.11 µM for GluA1-4 and Ki = 1.3-5.3 µM for different subtypes of Kainate receptors) and a negative allosteric modulator at NMDA receptor glycine binding site. Widely used for assessing the functional roles of neurotransmission mediated by glutamate receptors in both normal and abnormal brain functions.

Please note that the molecular weight for this compound is batch-specific due to variable water content.
Catalogue Number504914
Brand Family Calbiochem®
Synonyms6-Cyano-7-nitroquinoxaline-2,3-dione, 6-Cyano-2,3-dihydroxy-7-nitro-quinoxaline
References
ReferencesLee, S., et al. 2010. J. Neurophysiol. 103, 1728.
King, A., et al. 1992. Br. J. Pharmacol. 107, 375.
Long, S. et al. 1990. Br. J. Pharmacol. 100, 850.Harris, K., et al. 1989. Brain Res. 5, 185Honore, T., et al. 1988. Science. 241, 701.Birch, P., et al. 1988. Eur. J. Pharmacol. 156, 177.
Product Information
CAS number115066-14-3
FormOff-white to yellow solid
Hill FormulaC₉H₄N₄O₄
Chemical formulaC₉H₄N₄O₄
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetAMPA
Primary Target K<sub>i</sub>0.6 – 2.11 →M for GluA1 – 4 and Ki
Secondary targetKainate
Purity≥98% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
5.04914.0001 04055977263688

Documentation

CNQX - CAS 115066-14-3 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

CNQX - CAS 115066-14-3 - Calbiochem Certificates of Analysis

TitleLot Number
504914

References

Reference overview
Lee, S., et al. 2010. J. Neurophysiol. 103, 1728.
King, A., et al. 1992. Br. J. Pharmacol. 107, 375.
Long, S. et al. 1990. Br. J. Pharmacol. 100, 850.Harris, K., et al. 1989. Brain Res. 5, 185Honore, T., et al. 1988. Science. 241, 701.Birch, P., et al. 1988. Eur. J. Pharmacol. 156, 177.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision21-June-2024 JSW
Synonyms6-Cyano-7-nitroquinoxaline-2,3-dione, 6-Cyano-2,3-dihydroxy-7-nitro-quinoxaline
DescriptionA potent and competitive antagonist for AMPA/kainate receptors (Ki = 0.6 - 2.11 µM for GluA1-4 and Ki = 1.3-5.3 µM for different subtypes of Kainate receptors) and a negative allosteric modulator at NMDA receptor glycine binding site. Widely used for assessing the functional roles of neurotransmission mediated by glutamate receptors in both normal and abnormal brain functions.
FormOff-white to yellow solid
CAS number115066-14-3
Chemical formulaC₉H₄N₄O₄
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (25 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesLee, S., et al. 2010. J. Neurophysiol. 103, 1728.
King, A., et al. 1992. Br. J. Pharmacol. 107, 375.
Long, S. et al. 1990. Br. J. Pharmacol. 100, 850.Harris, K., et al. 1989. Brain Res. 5, 185Honore, T., et al. 1988. Science. 241, 701.Birch, P., et al. 1988. Eur. J. Pharmacol. 156, 177.